BIIB068 is a potent, selective, and orally bioavailable reversible inhibitor of Brutons tyrosine kinase (BTK), exhibiting an IC50 of 1 nM and high kinase selectivity. It is a valuable research tool for investigating BTKs role in B-cell malignancies and autoimmune disorders in both cellular and animal models.